Latest Communications

16 January 2013
MonoSol Rx Enters Into Licensing Agreement With Vestiq Pharmaceuticals for Zuplenz(R) Oral Soluble Film

19 November 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of two new Oral Dispersible Film (ODF) based respectively on Olanzapine and Donepezil

05 October 2012
Stellar Pharmaceuticals Launches New Migraine Treatment, CAMBIA®, in $150 Million Canadian Prescription Migraine Market


Oral

APR has a long experience in the oral pharmaceutical and nutraceutical formulations: a dynamic approach coupled with a solid background enables APR to offer the best and the most complete R&D support starting from galenic phase to a complete Dossier ready for filing.

APR has many years experience on the following pharmaceutical dosage forms:
> Conventional tablets
> Bi-layer tablets
> Micro-tablets
> Capsules
> Granulates
> Oral Dispersible Film (ODF)
> Oral Dispersible Tablets (ODT)
> Oral Dispersible Powder (ODP)

About Release Profile, APR is able to work and design the following profiles:
> Conventional release
> Immediate release
> Fast release
> Delayed release
> Dual Release (Fast and Extended)
> Prolonged/Extended release
> Taste masked formulation

About manufacturing processes, APR's experience ranges through all the following techniques:
> Direct Compression;
> Dry and Wet Granulation;
> Melt granulation;
> Cosmetic and Functional coating.




Search results